摘要
目的分析我院先天性心脏病相关性肺动脉高压的临床特点与药物治疗选用之间的关系。方法对我院心内科2009年1月至2011年12月确诊的98例先天性心脏病相关性肺动脉高压的临床资料以及治疗药物,结合2009年《欧洲肺动脉高压指南》进行回顾性分析。结果 98例患者中选择内皮素受体拮抗剂的有59例,选择5型磷酸二酯酶抑制剂的有14例,选择吸入用伊洛前列素的有11例,联合内皮素受体拮抗剂和5型磷酸二酯酶抑制剂治疗的有7例,联合伊洛前列素和5型磷酸二酯酶抑制剂治疗的有7例。在5型磷酸二酯酶抑制剂的选用方面,心功能Ⅱ级患者选用比例(33.3%)明显高于心功能Ⅲ级患者(7.4%)。各类特异性肺动脉治疗药物在肺动脉阻力和肺动脉收缩压分组中均有分布,且分布比例也相当,差异未见统计学意义。结论先天性心脏病相关性肺动脉高压患者在选用特异性肺动脉治疗药物治疗时与心功能级别相关,与肺动脉阻力和肺动脉收缩压关系不密切。
AIM To investigate the correlation between clinical characteristics and the selection of therapeutic drugs of congenital heart disease associated with pulmonary arterial hypertension （CHD-PAH） in our hospital. METH- ODS The clinical data and therapeutic drugs of 98 patients with CHD-PAH were retrospectively analyzed in the depart- ment of cardiology in our hospital from January 2009 to December 2011 according to the 2009 European guidelines for pulmonary arterial hypertension. RESULTS A total of 59 patients out of 98 patients were given endothelin receptor an- tagonists, 14 patients were given phosphodiesterase type 5 inhibitors, 11 patients were given the inhaled iloprost, 7 pa- tients were given endothelin receptor antagonists combined with phosphodiesterase type 5 inhibitors and 7 patients were given inhaled iloprost combined with phosphodiesterase type 5 inhibitors. Among the therapeutic drugs with phosphodi-esterase type 5 inhibitors, patients with cardiac function level Ⅱ （33.3 % ） were significantly higher than those with level Ⅲ （7.4%）. All kinds of specific pulmonary arterial hypertension drugs distributed equally in diverse pulmonary artery pressure and pulmonary artery systolic pressure subgroups with no statistieally significant differences. CONCLUSION The selection of therapeutic drugs for the CHD-PAH is related with cardiac funetion level and no correlation is found be- tween the therapeutic drugs with pulmonary artery pressure and pulmonary artery systolic pressure.
出处
《中国临床药学杂志》
CAS
2013年第6期354-357,共4页
Chinese Journal of Clinical Pharmacy
关键词
先天性心脏病
肺动脉高压
靶向药物治疗
congenital heart disease
pulmonary arterial hypertension
targeted drug therapy
